FDA
-
-
-
-
-
-
-
ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
-
-
-
-
-
-
-
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
-
-
-
-
-
-
-
ProKidney Corp. (PROK) PT Raised to $7 at Guggenheim
-
-
-
-
-
-
-
ProKidney Reports First Quarter 2025 Financial Results and Business Highlights
-
-
-
-
-
-
-
ProKidney to Participate in the UBS Virtual Organ Restoration Day
-
-
-
-
-
-
-
ProKidney Corp (PROK) Prices Upsized 53.72M Share Offering at $2.42/sh
-
-
-
-
-
-
-
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
-
335,407 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


